EPO and early-onset autosomal dominant Alzheimer disease: Given that only a single injection was given and beneficial effects observed up to 5 months later, this suggests that a genetic therapy propagating a non-hematopoietic Epo variant such as EpoR76E may be a viable treatment option for Alzheimer’s disease and other neurodegenerative conditions.